Publication at Faculty of Medicine in Hradec Králové |
2014
Abstract
Chronic obstructive pulmonary disease (COPD) represents growing global problem. The new aproaches for diagnosis, clasification a nd treatment of COPD are based on many new informations regarding the patophysiology of COPD and clinical symptoms accordingly.
Simultaneously developing whole new spectrum of drugs is offering more tergeted and more specific therapy. One of the main drugs with completely different mechanism of action targeted against latent inflammation, the essence of COPD, is roflumilast an PDE4 (phosphodiesterase 4) inhibitor.